Jarosław D Kasprzak is an expert in Cardiology at Medical University of Lodz (Poland). As of October 2026, ScienceLeadR ranks Jarosław D Kasprzak in the top 1% of experts worldwide for Myocardial Ischemia. Jarosław D Kasprzak has authored 824 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 2 of them ongoing. SLR score: 2,556 (community average: 125). How the SLR is computed.

LeadR Profile

Jarosław D Kasprzak Medical University of Lodz Poland
2 556 ScienceLeadR Reputation 2556
Network Map

Cardiology

Subspecialties: Medical Imaging - Public Health - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026

Source: PubMed

Medical University of Lodz

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 824

Citations

Citations: 21 323 1st author: 52 Last author: 329 Unique author: 9


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Longitudinal Changes in QTc Interval in Cancer Patients After the Initiation of Systemic Therapy: Analysis of the ONCOECHO Study Cohort.
PMID 42794903 — neoplasms, cohort studies, drug therapy, cardiotoxicity, therapeutics, electrocardiography, chemotherapy
Cancers (Basel)20260
Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial.
PMID 42770881 — stents, pilots, embolism, hemorrhage, stroke, ticagrelor, cardiovascular diseases, percutaneous coronary intervention, acute coronary syndrome, aspirin, atrial fibrillation, cardiology, coronary artery bypass, therapeutics, dabigatran
Cardiol J20260
Heart failure with improved ejection fraction: From diagnosis to management. Are phenotypes such as improvement, remission, and recovery possible? Expert opinion of the Heart Failure Association.
PMID 42578317 — heart failure, heart, cardiovascular system, phenotype, recycling, cardiology, diagnosis
Kardiol Pol20260
Infective endocarditis following transcatheter valvular interventions (transcatheter aortic valve implantation and transcatheter edge-to-edge repair).
PMID 42560291 — tomography, cardiovascular system, endocarditis, cardiology, aortic valve, transcatheter aortic valve replacement, diagnosis, therapeutics
Kardiol Pol20260
Prevalence, clinical significance, and risk factors of arrhythmic mitral valve prolapse - results of the MITPROL AR-PL Registry.
PMID 42484008 — registries, mitral valve, cardiovascular system, cardiology, signs and symptoms, prevalence, risk factors, mitral valve prolapse, prolapse
Kardiol Pol20260

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 12
N/A 6
Phase 2 4
Phase 3/Phase 4 1
Phase 4 1

By status:

Completed 16
Recruiting 5
Terminated 2
Unknown 1

By type:

Interventional 19
Observational 5

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 0
multicentric5to9 0
multicentricup10 15

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Prospective Open label Platform Study for Long term Follow up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies
2023-506791-27-00 — hypertension, hypertension, pulmonary, pulmonary arterial hypertension
Phase 3Recruiting2022
Evaluation of Safety and Efficacy of Two Ticagrelor based De escalation Antiplatelet Strategies in Acute Coronary Syndrome
NCT04718025 — safety, ticagrelor, acute coronary syndrome, aspirin, st elevation myocardial infarction, therapeutics, non-st elevated myocardial infarction, angina, unstable
Phase 3Recruiting2022

LeadR Networks

Main global connection map